Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Pandoraon Jul 12, 2023 5:23pm
298 Views
Post# 35538208

Some further action on a patent

Some further action on a patentCompany response to non-final rejection. USPTO now has 90 days to respond to the company's arguments.

17/192,597 | T1081/20078:

INACTIVATION OF PATHOGENS USING METAL-BASED COORDINATION COMPLEXES, AND METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MICROBIAL AND/OR VIRAL INFECTIONS

Public view
Application #

17/192,597

Confirmation #

8331

Attorney Docket #

T1081/20078

Patent #

-

Filing or 371 (c) date

03/04/2021

Status
Non Final Action Mailed



<< Previous
Bullboard Posts
Next >>